Exhibit 19.1

1000 Skokie Blvd., Suite 350

Wilmette, IL 60091

Telephone: (847) 388-0349

Date: March 3, 2025

Dear Officer, Director or Employee:

Enclosed is a memorandum from Monopar Therapeutics Inc.’s appointed Insider Trading Compliance Officer, a copy of the Company’s Confidential Insider Trading Policy, and, for officers and directors, a summary of the Ownership Reporting and Short-Swing Trading Rules under section 16 of the Securities Exchange Act of 1934. As described in the Insider Trading Policy, violations of the insider trading laws can result in significant civil and criminal liability. Accordingly, please take the time right now to read the materials provided, and then sign and return the attached copy of this letter.

Certification

The undersigned hereby certifies that he or she has read, understands and agrees to comply with the Company’s Confidential Insider Trading Policy and, if applicable, the summary of the Ownership Reporting and Short-Swing Trading Rules under section 16 of the Securities Exchange Act of 1934, copies of which were distributed with this letter.

Date: March 3, 2025

To:         All Employees, Officers and Directors of Monopar Therapeutics Inc. (the “Company”)

From: Quan Vu, Chief Financial Officer / Insider Trading Compliance Officer

Re:         Prohibition Against Insider Trading, and Confidentiality Obligations

The Company has adopted a formal Confidential Insider Trading Compliance Policy.

This memorandum is to emphasize the Company’s policy against “Insider Trading” and the importance of maintaining the confidentiality of sensitive information about the Company.

It is against Company policy and against the law for any employee, or any other person associated with the Company or its employees, to trade in our common stock or other securities while possessing Material Nonpublic Information or inside information about the Company. A violation of the laws against insider trading can lead to criminal prosecution resulting in prison terms of up to 20 years, and monetary penalties of U.S.$5,000,000 for individuals and of U.S.$25,000,000 for entities. A violation of the Company’s policy may also result in termination of employment.

Members of our Board of Directors and many employees have access to inside information about the Company at one time or another. Inside information is material information that is not available to the public but which an investor might consider important in deciding whether to buy or sell the Company’s stock. Inside information could include, as examples: financial results; projections of future earnings or losses; results of clinical trials or product development; actions of regulatory agencies; news of a pending or proposed merger or joint venture; news of the disposition of a subsidiary or significant assets; impending bankruptcy or financial liquidity problems; gain or loss of a substantial customer or supplier; new product announcements of a significant nature; significant product defects or modifications; significant pricing changes; stock splits or consolidations; new equity or debt offerings; acquisitions; significant litigation exposure due to actual or threatened litigation; and major changes in senior management.

In the event you possess inside information, you should not trade in our stock or other securities until the Company has publicly announced the information by press release or similar means, and the information has been available to the public for two full trading days.

Please do not disclose inside information to anyone outside the Company. It is important to maintain the confidentiality of sensitive information to protect the Company’s secrets and information that could benefit our competitors. It is also prudent from the perspective of your potential personal liability – you could be criminally and civilly liable for helping insider trading if you disclose inside information to another person and that person trades in the Company’s stock on the basis of your information (also called “tipping”).

Insider trading laws also apply to any inside information you may have regarding other companies, including information about our vendors and customers that you might obtain in the course of employment. In the event you hold inside information regarding another company, you should not trade in securities of that company until that company has publicly disclosed the information for two full trading days.

In addition, officers, directors and employees must pre-clear all trades with me. Attached is Company’s confidential policy on “Insider Trading”.

CONFIDENTIAL INSIDER TRADING POLICY

and Guidelines with Respect to

Certain Transactions in Company Securities

This Confidential Insider Trading Policy (the “Policy”) provides guidelines to employees, officers and directors of MONOPAR THERAPEUTICS INC. (the “Company”) with respect to transactions in the Company’s securities.

Applicability of Policy

This Policy applies to all transactions in the Company’s securities, including common stock, stock options and any other securities the Company may issue from time to time, such as restricted stock, restricted stock units, preferred stock, warrants and convertible debentures, as well as derivative securities relating to the Company’s stock, whether or not issued by the Company, such as exchange-traded options. It applies to all officers of the Company, all members of the Company’s Board of Directors and all employees of the Company. These individuals, members of their immediate families and members of their households are referred to in this Policy as “Insiders.” This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual’s own account.

Applicability of Policy to Inside Information

Regarding Other Companies

This Policy and the guidelines described herein also apply to Material Nonpublic Information (as defined below) relating to other companies, including the Company’s customers, collaborators, vendors or suppliers (“business partners”), when that information is obtained in the course of employment with, or other services performed on behalf of, the Company.

Civil and criminal penalties, and termination of employment, may result from trading on inside information regarding the Company’s business partners. All employees should treat Material Nonpublic Information about the Company’s business partners with the same care required with respect to Material Nonpublic Information related directly to the Company.

Definition of Material Nonpublic Information

Insider trading occurs when any person purchases or sells a security while in possession of inside information relating to the security. Inside information is information that is both material and nonpublic (“Material Nonpublic Information”). It is not possible to define all categories of Material Nonpublic Information. However, information should be regarded as material if there is a reasonable likelihood that it would be considered important to a reasonable investor in making an investment decision regarding the purchase or sale of the Company’s securities.

While it may be difficult under this standard to determine whether particular information is material, there are various categories of information that are particularly sensitive and, as a general rule, should always be considered material. Examples of such information may include:

Either positive or negative information may be material.

Nonpublic information is information that has not been previously disclosed to the general public and is otherwise not available to the general public.

Statement of Policy General Policy

It is the policy of the Company to prohibit the unauthorized disclosure of any nonpublic information and the use of Material Nonpublic Information in securities trading, and any other violation of applicable securities laws.

Potential Criminal and Civil Liability

and/or Disciplinary Action

Guidelines

Accordingly, to ensure compliance with this Policy and applicable federal and state securities laws, all Insiders shall refrain from conducting transactions involving the purchase or sale of the Company’s securities during the period beginning the first day of the first month of each quarter (i.e. January 1, April 1, July 1 and October 1) and ending two Trading Days following the date of public disclosure of the financial results for each fiscal quarter or year, approximately March 28, May 17, August 17, November 17, (the “Black-out Period”). Unless otherwise advised by the Insider Trading Compliance Officer, the Black-out Period shall be the period indicated above. The purpose behind the Black-out Period is to establish a preventative discipline to avoid any improper transactions.

In addition to scheduled Black-out Periods, from time to time, the Company may require that directors, officers, employees and others suspend trading because of developments known to the Company and not yet disclosed to the public. In such event, such persons may not engage in any transaction involving the purchase or sale of the Company’s securities during such period and should not disclose to others the fact of such suspension of trading.

It should be noted, however, that even outside the Black-out Period, any person possessing Material Nonpublic Information concerning the Company may not engage in any transactions in the Company’s securities until such information has been known publicly for at least two Trading Days, whether or not the Company has required a suspension of trading for that person. Assuming the absence of Material Nonpublic Information, trading in the Company’s securities outside of the Black-out Periods should not be considered a “safe harbor,” and all directors, officers, employees and other persons should use good judgment and consider external optics and other potential factors at all times.

Certain Exceptions

For the purposes of this Policy, the Company considers that the exercise of stock options for cash (but not any “cashless” exercise of options) under the Company’s stock options plans or the purchase of stock under an employee stock purchase plan (but not the sale of any such shares) is exempt from this Policy, since the other party to the transaction is the Company itself and the price does not vary with the market but is fixed by the terms of the stock option agreement or the plan. The surrender to or withholding by the Company of the Company’s securities (e.g., to cover withholding obligations upon the vesting or settlement of equity-based awards) are also exempt from this Policy.

Additionally, the settlement of trades that are outside of the control of the Insider, pursuant to a Rule 10b5- 1 plan, are not subject to the Blackout Periods or pre-clearance procedures described above. However, the establishment of a Rule 10b5-1 plan is subject to all elements of this Policy, including Blackout Periods and pre-clearance procedures. The Insider Trading Compliance Officer must clear the establishment of any Rule 10b5-1 plan by any officer, director or employee.

Additional Information – Directors and Officers

Insiders must comply with the reporting obligations and restrictions on short-swing transactions set forth in Section 16 of the Securities Exchange Act of 1934, as amended. The practical effect of these provisions is that officers and directors who purchase and sell, or sell and purchase, the Company’s securities within a six-month period must disgorge all profits to the Company whether or not they had knowledge of any Material Nonpublic Information. Under these provisions, and so long as certain other criteria are met, neither the receipt of a stock option under the Company’s stock option plans, nor the exercise of that option, nor the receipt of stock under an employee stock purchase plan, is deemed to be a purchase under Section 16; however, the sale of any such shares is a sale under Section 16. Moreover, no officer or director may ever make a short sale of the Company’s stock. The Company has provided, or will provide, separate memoranda and other appropriate materials to its officers and directors regarding compliance with Section 16 and its related rules.

The rules on recovery of short swing profits are absolute and do not depend on whether a person has Material Nonpublic Information.

In addition, the Company will not arrange with brokers to administer cashless exercises on behalf of directors and officers of the Company. Directors and officers of the Company may use the cashless exercise feature of their equity awards only if (i) the director or officer retains a broker independently of the Company, (ii) the Company’s involvement is limited to confirming that it will deliver the stock promptly upon payment of the exercise price and (iii) the director or officer uses a “T+3” cashless exercise arrangement, in which the Company agrees to deliver stock against the payment of the purchase price on the same day the sale of the stock underlying the equity award settles. Under a T+3 cashless exercise, a broker, the issuer and the issuer’s transfer agent work together to make all transactions settle simultaneously. This approach is to avoid any inference that the Company has “extended credit” in the form of a personal loan to the director or officer.

Communications with the Public

Only the executive officers who have been authorized to engage in communications with the public may disclose information to the public regarding the Company and its business activities and financial affairs. The public includes, without limitation, research analysts, portfolio managers, financial and business reporters, news media and investors. In addition, because of the risks associated with the exchange of information through such communications media, employees are strictly prohibited from posting or responding to messages containing information regarding the Company on Internet “bulletin boards,” Internet “chat rooms,” Facebook, LinkedIn, Twitter or in similar online social media forums.

The Company is required under the SEC’s Regulation FD to avoid the selective disclosure of Material Nonpublic Information. Accordingly, if you inadvertently disclosed any Material Nonpublic Information, immediately advise the Insider Trading Compliance Officer.

Inquiries

Please direct your questions as to any of the matters discussed in this Policy to the Company’s Insider Trading Compliance Officer.

MONOPAR THERAPEUTICS INC.

Insider Trading Compliance Program – Pre-clearance Form

*Must be Submitted No Later than Two Trading Days Before Estimated Trade Date*

The following section must be completed by the Individual Proposing to Trade:

Current Date:                                                                       

Individual Proposing to Trade:                                                                                                          

Proposed Trade (provide details - for example open market purchase of 1,000 shares of common stock on May 31, 20 , sale of 1,000 shares of common stock at $10.00 or better per share during the month of May, same day sale of 100 stock options with an exercise price of $10.00 per share at $15.00 or better per share until canceled):

As of the current date above, I am not in possession of Material Nonpublic Information as defined in the Company’s Insider Trading Policy.

Individual Proposing to Trade

The following section is to be completed by the Insider Trading Compliance Officer:

Insider Trading Compliance Officer